| Dr Nnenna E Ikeogu, MD | |
|
13013 Fuller Ave Ste A, Grandview, MO 64030-2687 | |
| (816) 214-5548 | |
| Not Available |
| Full Name | Dr Nnenna E Ikeogu |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 13013 Fuller Ave Ste A, Grandview, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104506211 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2023029385 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nnenna E Ikeogu, MD 3132 Lundin Dr Apt 4, Manhattan, KS 66503-2288 Ph: (607) 379-7631 | Dr Nnenna E Ikeogu, MD 13013 Fuller Ave Ste A, Grandview, MO 64030-2687 Ph: (816) 214-5548 |
News Archive
A research team from the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute has discovered a new class of small-molecule compounds that are good candidates for development of novel targeted therapies in the treatment of leukemia and lymphoma.
Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA.
ADInstruments is helping nursing students bridge the gap between the classroom and hospital ward with the latest version of LabTutor and three Nursing Experiment Collections. LabTutor 3.0 supports 19 new experiments (featuring over 100 exercises including patient case studies) that illustrate in practical terms the biological theory taught in nursing anatomy and physiology classrooms.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
› Verified 4 days ago
Dr. Hina Siddiqi, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13013 Fuller Ave Apt 3, Grandview, MO 64030 Phone: 516-451-3388 | |
Harry Lounce, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 12121 Blue Ridge Ext, Blue Ridge Family Physicians, Ste. M, Grandview, MO 64030 Phone: 816-761-0884 Fax: 816-716-1790 | |
Dr. Sami Bin Alam, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13013 Fuller Ave, Grandview, MO 64030 Phone: 816-214-5548 | |
Itoro Obot, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13013 Fuller Ave Ste A, Grandview, MO 64030 Phone: 816-214-5548 | |
Dr. Mohammed Haider Aldahan, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13013 Fuller Ave Ste A, Grandview, MO 64030 Phone: 816-214-5548 | |
Sami Daniel, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13013 Fuller Ave, Grandview, MO 64030 Phone: 816-214-5548 |